Skip to content
10-Q

Quarterly Report

Acrivon Therapeutics, Inc. ACRV

0001193125-26-221634

← back to feed
Filed
May 13, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 8, 2026 42.8M sh
Shares Diluted Q1 2026 · Mar 31, 2026 38.72M sh
Shares Diluted Q1 2026 · Mar 31, 2025 38.35M sh
Capex Q1 2026 · Mar 31, 2026 $14K
Capex Q1 2026 · Mar 31, 2025 $58K
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$20.54M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$19.54M
Short Term Investments Q1 2026 · Mar 31, 2026 $63.67M
Short Term Investments Q1 2026 · Dec 31, 2025 $77.08M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $34.06M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $41.5M
Cash And Equivalents Q1 2026 · Mar 31, 2025 $39.15M
Stockholders Equity Q1 2026 · Mar 31, 2026 $95.52M
Stockholders Equity Q1 2026 · Dec 31, 2025 $112.52M
Stockholders Equity Q1 2026 · Mar 31, 2025 $160.39M
Stockholders Equity Q1 2026 · Dec 31, 2024 $176.79M
Current Liabilities Q1 2026 · Mar 31, 2026 $11.05M
Current Liabilities Q1 2026 · Dec 31, 2025 $15.66M
Total Liabilities Q1 2026 · Mar 31, 2026 $12.32M
Total Liabilities Q1 2026 · Dec 31, 2025 $17.2M
Current Assets Q1 2026 · Mar 31, 2026 $99.22M
Current Assets Q1 2026 · Dec 31, 2025 $120.45M
Total Assets Q1 2026 · Mar 31, 2026 $107.83M
Total Assets Q1 2026 · Dec 31, 2025 $129.72M
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.49
Eps Diluted Q1 2026 · Mar 31, 2025 −$0.51
Eps Basic Q1 2026 · Mar 31, 2026 −$0.49
Eps Basic Q1 2026 · Mar 31, 2025 −$0.51
Sga Expense Q1 2026 · Mar 31, 2026 $4.74M
Sga Expense Q1 2026 · Mar 31, 2025 $6.25M
Rd Expense Q1 2026 · Mar 31, 2026 $15.17M
Rd Expense Q1 2026 · Mar 31, 2025 $15.41M
Net Income Q1 2026 · Mar 31, 2026 −$19.04M
Net Income Q1 2026 · Mar 31, 2025 −$19.68M
Operating Income Q1 2026 · Mar 31, 2026 −$19.9M
Operating Income Q1 2026 · Mar 31, 2025 −$21.66M